Research
D-Chiro-Inositol
20 peer-reviewed studies curated from PubMed and Semantic Scholar.
Studies
Sorted by quality and recency
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Meta-analysis of 48 studies (4451 women) evaluating insulin-sensitising drugs like metformin, D-chiro-inositol, rosiglitazone, and pioglitazone for women with PCOS. Metformin showed potential benefits for live birth rates and ovulation, but with gastrointestinal side effects. The evidence quality was low to moderate, and results varied by BMI.
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Meta-analysis of 44 trials involving 3992 women with PCOS assessing insulin-sensitising drugs like metformin and D-chiro-inositol. Metformin improved clinical pregnancy rates but not live birth rates, and was associated with gastrointestinal disturbances. The role of metformin in improving reproductive outcomes in women with PCOS appears limited.
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Meta-analysis of 31 trials involving 2537 women with PCOS, assessing insulin-sensitising drugs like metformin and D-chiro-inositol. Metformin improved clinical pregnancy and ovulation rates but did not improve live birth rates. Metformin was associated with gastrointestinal disturbances but no serious adverse effects.
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Meta-analysis of 31 trials involving 2537 women with PCOS, assessing insulin-sensitising drugs like metformin and D-chiro-inositol. Metformin improved clinical pregnancy and ovulation rates but did not improve live birth rates. Metformin was associated with gastrointestinal disturbances but no serious adverse effects.
D-chiro-inositol as a treatment in plaque psoriasis: A randomized placebo-controlled clinical trial.
This randomized placebo-controlled trial evaluated the effects of D-chiro-inositol (DCI) on mild plaque psoriasis in 46 psoriatic patients and 10 healthy volunteers. The study found that 1% DCI significantly increased hydration and elasticity of psoriatic lesions, although TEWL also increased. The results suggest that 1% DCI may be beneficial as an adjuvant treatment for psoriasis.
Exploring strengths and limits of urinary D-chiro inositol phosphoglycans (IPG-P) as a screening test for preeclampsia: A systematic review and meta-analysis.
Systematic review and meta-analysis of studies evaluating urinary D-chiro inositol phosphoglycans (IPG-P) as a screening test for preeclampsia. The analysis included seven studies, showing high sensitivity and specificity in identifying women who will develop preeclampsia. The findings suggest IPG-P as a promising noninvasive screening test, though further validation is needed.
D-Chiro-inositol and its significance in polycystic ovary syndrome: a systematic review.
Systematic review investigating the effects of D-chiro-inositol (DCI) on ovulation and insulin resistance in women with PCOS. DCI administration showed beneficial effects on ovulation and metabolic markers by enhancing insulin sensitivity, though study heterogeneity and small sample sizes limit conclusions.
Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome.
Meta-analysis of 15 RCTs assessing insulin sensitising drugs for PCOS, focusing on metformin. Metformin improved ovulation rates and reduced fasting insulin levels, blood pressure, and LDL cholesterol. It was associated with gastrointestinal disturbances but no serious adverse effects.
Modulatory role of D-chiro-inositol (DCI) on LH and insulin secretion in obese PCOS patients.
RCT evaluating the efficacy of D-chiro-inositol (DCI) on hormonal parameters and insulin sensitivity in overweight/obese PCOS patients. DCI administration improved insulin sensitivity, hormonal parameters, and BMI, with greater improvements in patients with diabetic relatives.
[Evaluation of the treatment with D-chiro-inositol on levels of oxidative stress in PCOS patients].
RCT assessing the effect of D-chiro-inositol on oxidative stress in the follicular fluid of women with PCOS. Treatment with D-chiro-inositol reduced the oxidation of thiol groups, suggesting a decrease in oxidative stress.
High dose of d-chiro-inositol improves oocyte quality in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial.
RCT evaluating the effect of two doses of d-chiro-inositol (DCI) in combination with Myo-inositol (MYO) on oocyte quality in women with PCOS undergoing ICSI. High doses of DCI improved oocyte cytoplasm quality, zona pellucida, plasma membrane, and sperm reception.
A pilot study of D-chiro-inositol plus folic acid in overweight patients with type 1 diabetes.
A 24-week randomized control trial in 26 overweight or obese T1D patients evaluated the effect of D-chiro-inositol plus folic acid on metabolic control. The treated group showed a significant reduction in HbA1c levels compared to the control group, but no significant changes in BMI or insulin requirement were observed.
Insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator correlates with insulin sensitivity in women with polycystic ovary syndrome.
RCT of D-chiro-inositol (DCI) supplementation vs placebo in 11 women with PCOS, assessing plasma DCI, DCI-IPG release, and insulin sensitivity over 6 weeks. Positive correlation found between increased DCI-IPG release and improved insulin sensitivity, suggesting DCI-IPG as a potential therapeutic target in PCOS.
Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome.
RCT in 20 lean women with polycystic ovary syndrome comparing 600 mg D-chiro-inositol to placebo for 6 to 8 weeks. D-chiro-inositol reduced circulating insulin, decreased serum androgens, and improved metabolic abnormalities such as blood pressure and triglyceride levels.
Phosphoinositol glycan derived mediators and insulin resistance. Prospects for diagnosis and therapy.
The study investigates the role of phosphoinositol glycan (IPG) derived mediators in insulin resistance, highlighting the significance of D-chiro-inositol. D-chiro-inositol administration decreased hyperglycemia and enhanced glucose disposal in STZ diabetic rats, rhesus monkeys, and humans with impaired glucose tolerance and PCOS, suggesting its potential in reversing insulin resistance.
Hawthorn polyphenols, D-chiro-inositol, and epigallocatechin gallate exert a synergistic hypoglycemic effect.
The study investigates the hypoglycemic effects of a glucose-lowering complex (DEH) consisting of hawthorn polyphenols, D-chiro-inositol, and epigallocatechin gallate. In STZ/HFD-induced mice, DEH improved insulin resistance, reduced fasting blood glucose, and increased hepatic glycogen synthesis and storage, suggesting its potential as a novel strategy for type 2 diabetes treatment.
Uncoupling between insulin and release of a D-chiro-inositol-containing inositolphosphoglycan mediator of insulin action in obese women With polycystic ovary syndrome.
Cross-sectional case-control study comparing the release of DCI-IPG between normal nonobese women and obese PCOS women during insulin stimulation. The study found that DCI-IPG bioactivity was significantly lower in PCOS women, indicating impaired coupling between insulin action and DCI-IPG release, which may contribute to insulin resistance.
Metformin therapy increases insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator in women with polycystic ovary syndrome.
RCT in 19 obese women with PCOS comparing metformin to placebo over 4-8 weeks. Metformin increased the ratio of DCI-IPG to insulin, suggesting improved insulin action through enhanced release of DCI-IPG mediators.
Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome.
RCT of 44 obese women with polycystic ovary syndrome comparing 1200 mg of D-chiro-inositol to placebo for six to eight weeks. D-chiro-inositol improved insulin sensitivity, ovulatory function, and decreased serum androgen concentrations, blood pressure, and plasma triglyceride concentrations.
Can high levels of D-chiro-inositol in follicular fluid exert detrimental effects on blastocyst quality?
Prospective observational study involving eight egg donors and eleven couples undergoing IVF, examining the correlation between myo-inositol/D-chiro-inositol ratio in follicular fluid and blastocyst quality. Higher myo-inositol/D-chiro-inositol ratios were associated with better quality blastocysts, suggesting that lower D-chiro-inositol content may improve ART outcomes.